Exercise of Options, PDMR Dealing and TVR

RNS Number : 0520X

CVS Group plc

04 January 2022

 

4 January 2022

CVS Group Plc

("CVS", the "Company" or the "Group")

Exercise of Options, PDMR Dealing and Total Voting Rights

CVS, one of the UK's leading providers of integrated veterinary services, announces that on 4 January 2022, options over a total of 63,320 new ordinary shares of 0.2 pence each (the "New Shares") were exercised under the CVS Group 2018 SAYE Plan (2018/2021), at an exercise price of £8.30.

Richard Fairman, Chief Executive Officer, and Ben Jacklin, Chief Operating Officer, each exercised options over 737 ordinary shares of 0.2p in the Company ("Ordinary Shares").  The balance of the options were exercised by certain other employees and former employees of the Company.

Following their respective option exercises, Richard Fairman holds a beneficial interest in 29,462 Ordinary Shares in the Company, representing approximately 0.042 per cent of the total voting rights of the Company following the issue of the New  Shares, and Ben Jacklin holds a beneficial interest in 5,446 Ordinary Shares in the Company, representing approximately 0.008 per cent of the total voting rights of the Company, calculated on the same basis.

Following the issue of the New Shares, the Company has a total issued share capital of 70,934,113 Ordinary Shares each carrying one voting right. The Company holds no Ordinary Shares in treasury. Therefore, following the issue of the New Shares, the total number of voting rights in the Company will be 70,934,113. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

This announcement is released by CVS Group plc and contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"), encompassing information relating to trading for the Company's current financial year, and is disclosed in accordance with the Company's obligations under UK MAR. This announcement is being made on behalf of the Company by the director named below.

Contacts:

CVSGroupplc	viaMHPCommunications
RichardFairman,CEO
JennyFarrer,CompanySecretary
SingerCapitalMarkets(NominatedAdviser&Broker)	[phone]
AubreyPowell /JenBoorer/Rachel Hayes
MHPCommunications(FinancialPR)	[phone]
AndrewJaques/Rachel Mann/CharlesHirst

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closelyassociated
a)	Name	Richard Fairman
2	Reason forthenotification
a)	Position/status	ChiefExecutiveOfficer
b)	Initialnotification/Amendment	InitialNotification
3	Details of the issuer, emission allowance market participant, auction platform,auctioneer orauctionmonitor
a)	Name	CVSGroup plc
b)	LEI	213800J41XDQ2NX48O05
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)each type of transaction; (iii) each date; and (iv) each place where transactions havebeenconducted

a)	Description of the financialinstrument,typeof instrument Identificationcode	Ordinarysharesof0.2penceeach GB00B2863827
b)	Natureofthetransaction	Exerciseofoptionsunder the 2018 SAYE Plan (1 January  2022 maturity)
c)	Price(s)andvolume(s)
d)	Aggregatedinformation - Aggregatedvolume - Price	N/A - single transaction
e)	Dateofthetransaction	4 January 2022
f)	Placeofthetransaction	LondonStock Exchange

1	Details of the person discharging managerial responsibilities / person closelyassociated
a)	Name	BenJacklin
2	Reason forthenotification
a)	Position/status	ChiefOperatingOfficer
b)	Initialnotification/Amendment	InitialNotification
3	Details of the issuer, emission allowance market participant, auction platform,auctioneer orauctionmonitor
a)	Name	CVSGroup plc
b)	LEI	213800J41XDQ2NX48O05
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)each type of transaction; (iii) each date; and (iv) each place where transactions havebeenconducted
a)	Description of the financialinstrument,typeof instrument Identificationcode	Ordinarysharesof0.2penceeach GB00B2863827
b)	Natureofthetransaction	Exerciseofoptionsunder the 2018 SAYE Plan (1 January 2022 maturity)
c)	Price(s)andvolume(s)
			Price(s)	Volume(s)
			£8.30	737

d)	Aggregatedinformation - Aggregatedvolume - Price	N/A - single transaction
e)	Dateofthetransaction	4 January 2022
f)	Placeofthetransaction	LondonStock Exchange

 

END

 

 

IOEKBLBXFLLZFBF